Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Global Healthy Living Foundation has 12 posters and Polymyalygia Rheumataca, Psoriasis and RA Research at American College of ...

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...

Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and ...

Johnson & Johnson announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% ...

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer Presentations ...

Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months ...

In the technical session, Bijay Singh, former ICAR national professor at PAU, Ludhiana, emphasised the need to rethink ...

Codexis Demonstrates First-ever Enzymatic Synthesis of Approved siRNA Therapeutic ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity ...